IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2
Authors:
- Malika HaleMHMalika Hale
- Jason NetlandJNJason Netland
- Yu ChenYCYu Chen
- Christopher D. ThouvenelCTChristopher D. Thouvenel
- Katherine Nabel SmithKSKatherine Nabel Smith
- Lucille M. RichLRLucille M. Rich
- Elizabeth R. VanderwallEVElizabeth R. Vanderwall
- Marcos C. MirandaMMMarcos C. Miranda
- Julie EggenbergerJEJulie Eggenberger
- Linhui HaoLHLinhui Hao
- Michael J. WatsonMWMichael J. Watson
- Charles C. MundorffCMCharles C. Mundorff
Open Access
- 8 August 2022
- journal article
- research article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (9)
Abstract
Humoral immunity to SARS-CoV-2 can be supplemented with polyclonal sera from convalescent donors or an engineered monoclonal antibody (mAb) product. While pentameric IgM antibodies are responsible for much of convalescent sera’s neutralizing capacity, all available mAbs are based on the monomeric IgG antibody subtype. We now show that IgM mAbs derived from immune memory B cell receptors are potent neutralizers of SARS-CoV-2. IgM mAbs outperformed clonally identical IgG antibodies across a range of affinities and SARS-CoV-2 receptor-binding domain epitopes. Strikingly, efficacy against SARS-CoV-2 viral variants was retained for IgM but not for clonally identical IgG. To investigate the biological role for IgM memory in SARS-CoV-2, we also generated IgM mAbs from antigen-experienced IgM+ memory B cells in convalescent donors, identifying a potent neutralizing antibody. Our results highlight the therapeutic potential of IgM mAbs and inform our understanding of the role for IgM memory against a rapidly mutating pathogen.Keywords
Funding Information
- Burroughs Wellcome Fund
- Bill and Melinda Gates Foundation (OPP1156262)
- Bill and Melinda Gates Foundation (OPP1126258)
- National Institutes of Health (T32GM007266)
- National Institutes of Health (T32GM007753)
- National Institutes of Health (R01AI153191)
- National Institutes of Health (R01AI163160)
- National Institutes of Health (K24AI150991-01S1)
This publication has 64 references indexed in Scilit:
- Site-SpecificN-Glycosylation of Recombinant Pentameric and Hexameric Human IgMJournal of the American Society for Mass Spectrometry, 2016
- Intra-Spike Crosslinking Overcomes Antibody Evasion by HIV-1Cell, 2015
- IMGT® Tools for the Nucleotide Analysis of Immunoglobulin (IG) and T Cell Receptor (TR) V-(D)-J Repertoires, Polymorphisms, and IG Mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS2012
- Germinal CentersAnnual Review of Immunology, 2012
- Protective effect of IgM against colonization of the respiratory tract by nontypeable Haemophilus influenzae in patients with hypogammaglobulinemiaJournal of Allergy and Clinical Immunology, 2012
- A germinal center–independent pathway generates unswitched memory B cells early in the primary responseJournal of Experimental Medicine, 2012
- Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutantsJournal of Experimental Medicine, 2011
- The human IgM pentamer is a mushroom-shaped molecule with a flexural biasProceedings of the National Academy of Sciences, 2009
- Determination of Carbohydrate Contents from Excess Light ScatteringAnalytical Biochemistry, 2001
- Production of IgM Hexamers by Normal and Autoimmune B Cells: Implications for the Physiologic Role of Hexameric IgMThe Journal of Immunology, 1998